Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine

BIOLOGICAL3 trials

Sponsors

Mayo Clinic

Conditions

Advanced Fallopian Tube CarcinomaAdvanced Fallopian Tube High Grade Serous AdenocarcinomaAdvanced Ovarian CarcinomaAdvanced Ovarian CarcinosarcomaAdvanced Ovarian Clear Cell AdenocarcinomaAdvanced Ovarian Endometrioid AdenocarcinomaAdvanced Ovarian High Grade Serous AdenocarcinomaAdvanced Primary Peritoneal Carcinoma

Early Phase 1

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

CompletedNCT02111941

Mayo ClinicFallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm +20

Start: 2014-04-14End: 2021-07-27Updated: 2025-10-31

Phase 1

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

RecruitingNCT05920798

Mayo ClinicFallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma +13

Start: 2023-09-28End: 2027-07-15Target: 40Updated: 2025-06-22

Phase 2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

RecruitingNCT06639074

Mayo ClinicAdvanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma +15

Start: 2024-11-08End: 2027-12-31Target: 78Updated: 2025-10-02

Related Papers

Abstract TMEM-016: DENDRITIC CELL VACCINATION AND INHIBITION OF TUMOR–ASSOCIATED IMMUNE SUPPRESSION

Clinical Cancer Research2017-05-31